- The test uses the company’s digital platform with GRAIL’s advanced cancer screening technology.
- The multi-cancer early detection test identifies cancers signals that currently lack recommended screening methods.
- The company is expected to report its fourth-quarter and full-year 2025 results on February 23.
Hims & Hers Health, Inc. (HIMS) came under the spotlight on Wednesday after the company unveiled a blood test to detect signals for more than 50 types of cancer, often before symptoms appear.
Called the Hims & Hers Multi-Cancer Test by Galleri, the test uses the company’s digital platform with GRAIL’s advanced cancer screening technology. The multi-cancer early detection test identifies shared cancer signals, including those for cancers that currently lack recommended screening methods.
“GRAIL believes making validated MCED tests available as a complement to recommended cancer screenings can help to increase cancer detection before cancers spread, improve outcomes, and enable this breakthrough technology to be available to more people,” said Josh Ofman, President at GRAIL.
HIMS was among the top trending tickers on Stocktwits while the shares edged 1% lower after the opening bell.
Stocktwits Users Reaction
Despite the intraday drop, retail sentiment on Stocktwits turned 'bullish' from 'neutral' a day earlier, amid 'high' message volumes.
One user said the news could become a big growth catalyst for the company.
Another user said "preventative healthcare is the future."
The stock has been under selling pressure lately, slumping more than 25% so far this year.
Hims & Hers Health is expected to report its fourth-quarter (Q4) and full-year 2025 financial results on February 23. During its Q3 report, the company had guided FY2025 revenue between $2.335 billion and $2.355 billion and adjusted earnings guidance between $307 million and $317 million.
Read also: BSX Stock Tumbles Pre-Market On Softer 2026 Sales Growth Forecast
For updates and corrections, email newsroom[at]stocktwits[dot]com.